Iovance Biotherapeutics Inc (NASDAQ:IOVA) currently has a daily average trading volume of 7.27M but it saw 7391198 shares traded in last market. With a market cap of 3.07B USD, the company’s current market price of $10.11 came falling about -5.87 while comparing to the previous closing price of $10.74. In past 52 weeks, the stock remained buoying in the range of price level as high as $18.33 and as low as $3.21. In the recent trading on the day, stock has struck highest price mark of $9.87 while lowest mark touched by it was $10.93.
Taking a look at 20-day trading activity of Iovance Biotherapeutics Inc (IOVA) gives us an average price of $8.75, while its current price level is -44.84% below from 52-week high level whereas it is 214.95% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $8.39 while that of 200 days or SMA-200 reads an average of $9.57. A closer look into the stock’s movement over the week reveals that its volatility is standing at 11.26% during that period while stretching the period over a month that decreases to 8.63%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 60.70 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Piper Sandler which downgraded the stock as “Neutral” in its note to investors issued on July 29, 2024, recommending a price target of between $19 and $10 for it. Barclays issued its recommendations for the stock as it reiterated the price target for the stock in the range of between $40 and $18.
Over the week, IOVA’s stock price is moving 37.93% up while it is 7.44% when we observe its performance for the past one month. Year-to-date it is 24.35% up and over the past year, the stock is showing an upside performance of 41.99%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.46 beaten by the consensus estimate of -0.45 for the same. In next quarter, company is expected to be making quarterly sales of $77.5M as analysts are expecting the sales for current fiscal year at $162.99M and seeing the company making $465.57M in sales next year. Moreover, analysts are in estimates of $54.01M for current-quarter revenue.
Currently, Iovance Biotherapeutics Inc’s total number of outstanding shares is 256.14M with 0.50% of that held by the insiders while 82.14% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -52.48% and return on equity (ROE) at -65.36%. Stock’s beta reads 0.56. Stock has a price to book (P/B) ratio of 3.91 while price to sale or P/S ratio amounts to 93.64. Its return on asset (ROA) is -51.14% on average.
